var data={"title":"Daptomycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Daptomycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5979?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=daptomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Daptomycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Daptomycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156919\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cubicin;</li>\n      <li>Cubicin RF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6127324\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cubicin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156936\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Cyclic Lipopeptide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156921\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic foot infections without osteomyelitis (off-label use):</b> IV: 4 mg/kg once daily (Lipsky 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. aureus</i> (right-sided, native valve): <b>Note: </b>Clinical trial demonstrating noninferiority to standard therapy for <i>S. aureus</i> right-sided endocarditis included only patients with native valve infective endocarditis (Fowler 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer labeling: </i>6 mg/kg once daily for 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendation:</i> 8 to 10 mg/kg once daily (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. aureus</i> (left-sided, native valve) (off-label use): &ge;8 mg/kg once daily for 6 weeks, consultation with infectious disease specialist recommended for dosage selection (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus</i> (penicillin-, aminoglycoside-, and vancomycin-resistant) (off-label use): 10 to 12 mg/kg once daily for a minimum of 6 weeks; combination therapy with ampicillin, ceftaroline, or another antibiotic may be considered in patients with persistent bacteremia or strains with relatively high MICs to daptomycin within the susceptible range (&lt;4 mcg/mL) (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis due to MRSA (off-label use):</b> IV: 6 mg/kg once daily for a minimum of 8 weeks; some experts combine with rifampin (in patients with concurrent bacteremia, initiate rifampin after clearance of bacteremia) (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis, native vertebral (off-label use) (IDSA [Berbari 2015]): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Staphylococci (oxacillin-susceptible or -resistant): 6 to 8 mg/kg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus</i> spp (penicillin-susceptible or -resistant): 6 mg/kg once daily for 6 weeks. <b>Note:</b> In patients with infective endocarditis, the addition of an aminoglycoside for 4 to 6 weeks is recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Enterococcus spp (penicillin-susceptible or -resistant) (alternative treatment):</i> 6 mg/kg every 24 hours for 4 to 6 weeks (consider adding an aminoglycoside), followed by an oral antibiotic suppressive regimen if a debridement and retention strategy or 1-stage exchange is chosen (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Staphylococci (oxacillin-susceptible or -resistant) (alternative treatment):</i> 6 mg/kg every 24 hours for 2 to 6 weeks (used in combination with rifampin if a debridement and retention strategy or 1-stage exchange is chosen), followed by oral antibiotic treatment (and suppressive regimen if a debridement and retention strategy or 1-stage exchange is chosen) (Osmon 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>S. aureus </b></i>\n      <b>bacteremia:</b> IV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer labeling: </i>6 mg/kg once daily for 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendation:</i> 8 to 10 mg/kg once daily for complicated bacteremia (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic arthritis due to MRSA (off-label use):</b> IV: 6 mg/kg once daily for 3 to 4 weeks (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections, complicated:</b> IV: 4 mg/kg once daily for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VRE bacteremia (off-label use):</b> IV: 6 to 8 mg/kg once daily (Casapao 2013; Gallagher 2009); however, based on pharmacokinetic data, higher doses (up to 12 mg/kg once daily) may be appropriate for difficult to treat infections (Benvenuto 2006). Additional trials may be necessary to further define the role of daptomycin in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50085848\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Daptomycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Endocarditis, treatment (off-label use; AHA [Baltimore 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Due to <i>Staphylococcus</i> (MRSA or vancomycin resistant/intolerant): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;6 years: 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents: 6 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections, complicated:</b> Children and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to &lt;2 years: 10 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2 to 6 years: 9 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 to 11 years: 7 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">12 to 17 years: 5 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;18 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy: &le;14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>S. aureus</i> bacteremia:</b> Children and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 6 years: 12 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 to 11 years: 9 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">12 to 17 years: 7 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;18 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy: &le;42 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156922\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156923\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Skin and soft tissue infections: 4 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Staphylococcal bacteremia: 6 mg/kg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): <b>Note:</b> Hemodialysis: Dialyzable: 15% (removed by 4-hour hemodialysis session); 50% (removed by 4-hour high permeability intermittent hemodialysis session) (Salama 2010). A notable amount of drug may be removed in the last 30 minutes of dialysis; administration after dialysis is completed is preferred (Haselden 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> Dose as in CrCl &lt;30 mL/minute (administer after hemodialysis on dialysis days).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> Administer usual recommended dose (ie, 4 or 6 mg/kg) on 48 hour intradialytic days; increase dose by 50% after dialysis on the 72 hour intradialytic day (eg, if the dose is 6 mg/kg for a patient on a Monday, Wednesday, Friday dialysis schedule, administer 6 mg/kg after dialysis on Monday and Wednesday and on Friday administer <b>9 mg/kg</b> after dialysis) (Haselden 2013, Patel 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): Dose as in CrCl &lt;30 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous veno-venous hemodialysis (CVVHD): 8 mg/kg every 48 hours (Vilay 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> For other forms of CRRT (eg, CVVH or CVVHDF), dosing as with CrCl &lt;30 mL/minute may result in low C<sub>max</sub>. May consider 4 to 6 mg/kg every 24 hours (or 8 mg/kg every 48 hours) depending on site or severity of infection or if not responding to standard dosing; therapeutic drug monitoring and/or more frequent serum CPK levels may be necessary (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Slow extended daily dialysis (or extended dialysis): 6 mg/kg every 24 hours (Kielstein 2010); <b>Note:</b> Dialysis should be initiated within 8 hours of administering daptomycin dose to avoid dose accumulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1959284\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156900\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cubicin: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cubicin RF: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156888\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156904\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as an IV infusion over 30 minutes (children and adolescents 7 to 17 years of age and adults) or 60 minutes (children 1 to 6 years of age). May also administer IV push over 2 minutes in adults only; <b>do not</b> administer IV push to pediatric patients. Do not use in conjunction with ReadyMED&reg; elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) leaching from the pump system into the daptomycin solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156903\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections, complicated:</b> Treatment of complicated skin and skin structure infections caused by <i>Staphylococcus aureus</i> (including methicillin-resistant isolates), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, <i>Streptococcus dysgalactiae</i> subspecies <i>equisimilis</i>, and <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only) in adult and pediatric patients 1 to 17 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>S. aureus</b></i> <b>bacteremia:</b> Treatment of <i>S. aureus</i> (methicillin-susceptible and methicillin-resistant isolates) bacteremia in adults, including those with right-sided infective endocarditis; treatment of <i>S. aureus</i> bacteremia in pediatric patients 1 to 17 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for the treatment of pneumonia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475182\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Diabetic foot infections; Endocarditis (due to S. aureus [left-sided] or Enterococcus), treatment (adults); Endocarditis, treatment (pediatric); Osteomyelitis and/or septic arthritis due to methicillin-resistant Staphylococcus aureus; Osteomyelitis, native vertebral; Prosthetic joint infection caused by staphylococci (oxacillin-susceptible or -resistant) or Enterococcus (penicillin-susceptible or -resistant); Vancomycin-resistant enterococci (VRE) bacteremia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3265806\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cubicin may be confused with Cleocin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DAPTOmycin may be confused with DACTINomycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Storage and preparations errors have occurred when Cubicin has been confused with Cubicin RF (ISMP 2016)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156892\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (adults: 7%), edema (adults: 7%), hypertension (adults: 6%), hypotension (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (adults: 9%), headache (3% to 5%), dizziness (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (3% to 6%), diaphoresis (adults: 5%), skin rash (adults: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (5% to 7%), abdominal pain (adults: 6%; children and adolescents: 2%), vomiting (children and adolescents: 3% to 11%; adults: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (adults: 3%), increased serum alkaline phosphatase (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Gram-negative organism infection (adults: 8%), bacteremia (adults: 5%), sepsis (adults: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (3% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngolaryngeal pain (adults: 8%), dyspnea (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, atrial flutter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hallucination, hypoesthesia (including oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum phosphate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite, epigastric distress, gingival pain, oral candidiasis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Fungal urinary tract infection, proteinuria, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis, fungal septicemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Dyskinesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distension, acute generalized exanthematous pustulosis, acute renal failure, anaphylaxis, anemia, arthralgia, bronchiolitis obliterans organizing pneumonia, <i>Clostridium difficile-</i>associated diarrhea, cough, decreased appetite, dysgeusia, eczema, electrolyte disturbance, eosinophilia, eosinophilic pneumonitis, eye irritation, fatigue, flushing, hypomagnesemia, hypersensitivity reaction (including angioedema, drug rash with eosinophilia and systemic symptoms [DRESS], dysphagia, hives, pulmonary eosinophilia, truncal erythema), increased lactate dehydrogenase, increased myoglobin, increased serum bicarbonate, jaundice, leukocytosis, mental status changes, muscle cramps, myalgia, myasthenia, myopathy, nausea, neutropenia (Knoll 2013), paresthesia, peripheral neuropathy, renal failure, rhabdomyolysis, rigors, Stevens-Johnson syndrome, stomatitis, supraventricular cardiac arrhythmia, thrombocythemia, thrombocytopenia, vertigo, vesiculobullous dermatitis, visual disturbance, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156907\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to daptomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156890\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Eosinophilic pneumonia: Use may result in eosinophilic pneumonia; generally develops 2 to 4 weeks after therapy initiation. Monitor for signs and symptoms of eosinophilic pneumonia, including new onset or worsening fever, dyspnea, difficulty breathing, new infiltrates on chest imaging studies, and/or &gt;25% eosinophils present in bronchoalveolar lavage. Discontinue use immediately with signs/symptoms of eosinophilic pneumonia and initiate appropriate treatment (ie, corticosteroids). May reoccur with re-exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions and anaphylaxis (including angioedema, and drug rash with eosinophilia and systemic symptoms [DRESS]) have been reported with use; discontinue use immediately with signs/symptoms of hypersensitivity and initiate appropriate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: May be associated with an increased incidence of myopathy; rhabdomyolysis, with or without acute renal failure, has also been reported. Discontinue in patients with signs and symptoms of myopathy in conjunction with an increase in CPK (&gt;5 times ULN or 1,000 units/L) or in asymptomatic patients with a CPK &ge;10 times ULN or &gt;2,000 units/L. Myopathy may occur more frequently at dose and/or frequency in excess of recommended dosages. Consider temporarily interrupting therapy with other agents associated with rhabdomyolysis (eg, HMG-CoA reductase inhibitors) during daptomycin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Symptoms suggestive of peripheral neuropathy have been observed with treatment; monitor for new-onset or worsening neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persisting or relapsing <i>S. aureus</i> bacteremia or endocarditis: Repeat blood cultures in patients with persisting or relapsing <i>S. aureus</i> bacteremia/endocarditis or poor clinical response. If culture is positive for <i>S. aureus</i>, perform minimum inhibitory concentration (MIC) susceptibility testing of the isolate and diagnostic evaluation of the patient to rule out sequestered foci of infection. Appropriate surgical intervention (eg, debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial therapy may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe renal impairment (CrCl &lt;30 mL/minute). Limited data (eg, subgroup analysis) from cSSSI and endocarditis trials suggest possibly reduced clinical efficacy (relative to comparators) in patients with baseline moderate to severe renal impairment (&lt;50 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Avoid use in pediatric patients &lt;12 months due to risk of potential muscular, neuromuscular, and/or nervous systems effects observed in neonatal canines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299126\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156894\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9304&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): May enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156909\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Successful use of daptomycin during the second and third trimesters of pregnancy has been described; however, only limited information is available from case reports.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063936\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low concentrations of daptomycin have been detected in breast milk; however, daptomycin is poorly absorbed orally. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156898\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor signs and symptoms of infection. CPK should be monitored at least weekly during therapy; more frequent monitoring if current or prior statin therapy, unexplained CPK increases, and/or renal impairment. Monitor for muscle pain or weakness, especially if noted in distal extremities. Monitor for new onset or worsening peripheral neuropathy. Monitor for signs/symptoms of eosinophilic pneumonia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156901\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trough concentrations at steady-state:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 mg/kg once daily: 5.9 &plusmn; 1.6 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 mg/kg once daily: 6.7 &plusmn; 1.6 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Routine trough monitoring is not recommended. Trough concentrations are not predictive of efficacy. Drug exhibits concentration-dependent bactericidal activity, so C<sub>max</sub>:MIC ratios may be a more useful parameter for efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156889\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Daptomycin binds to components of the cell membrane of susceptible organisms and causes rapid depolarization, inhibiting intracellular synthesis of DNA, RNA, and protein. Daptomycin is bactericidal in a concentration-dependent manner.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156906\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months: Median: 0.21 L/kg (range: 0.11 to 0.34 L/kg) (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 0.14 L/kg (Abdel-Rahman 2008; Abdel-Rahman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 17 years: 0.11 &plusmn; 0.02 L/kg (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.1 L/kg; Critically-ill patients: V<sub>ss</sub>: 0.23 &plusmn; 0.14 L/kg (Vilay 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 90% to 93%; 84% to 88% in patients with CrCl &lt;30 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor amounts of oxidative metabolites have been detected</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months: Median: 6.2 hours (range: 3.7 to 9 hours) (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: Mean range: 5.3 to 5.7 hours (Abdel-Rahman 2008; Abdel-Rahman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 11 years: 5.6 &plusmn; 2.2 hours (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 12 to 17 years: 6.7 &plusmn; 2.2 hours (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 8 to 9 hours (up to 28 hours in renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (78%; primarily as unchanged drug); feces (5.7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates and Infants &lt;3 months: Median: 21 mL/hour/kg (range: 16 to 34 mL/hour/kg) (Cohen-Wolkowiez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 19 to 20 mL/hour/kg (Abdel-Rahman 2008; Abdel-Rahman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 7 to 11 years: 17 mL/hour/kg (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 12 to 17 years: 11 mL/hour/kg (Abdel-Rahman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 8.3 to 9 mL/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323093\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cubicin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $534.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cubicin RF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $534.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (DAPTOmycin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $534.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539841\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cubicin (AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IN, IS, IT, JO, JP, KR, KW, LT, MT, MY, NL, NO, NZ, PH, PL, PT, QA, RO, RU, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Kubitsyn (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM, Benziger DP, Jacobs RF, et al, &quot;Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections,&quot; <i>Pediatr Infect Dis J</i>, 2008, 27(4):330-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18316988/pubmed\" target=\"_blank\" id=\"18316988\">18316988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM, Chandorkar G, Akins RL, et al, &quot;Single-Dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-Positive Infections,&quot; <i>Pediatr Infect Dis J</i>, 2011, 30(8):712-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21317681/pubmed\" target=\"_blank\" id=\"21317681\">21317681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ardura MI, Mej&iacute;as A, Katz KS, et al, &quot;Daptomycin Therapy for Invasive Gram-Positive Bacterial Infections in Children,&quot;<i> Pediatr Infect Dis J</i>, 2007, 26(12):1128-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18043450/pubmed\" target=\"_blank\" id=\"18043450\">18043450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. <i>Antimicrob Agents Chemother</i>. 2006;50(10):3245-3249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/17005801/pubmed\" target=\"_blank\" id=\"17005801\">17005801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26229122/pubmed\" target=\"_blank\" id=\"26229122\">26229122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26063715\"></a>Britt NS, Potter EM, Patel N, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. <i>Clin Infect Dis</i>. 2015;61(6):871-878.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26063715/pubmed\" target=\"_blank\" id=\"26063715\">26063715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24080644\"></a>Carugati M, Bayer AS, Mir&oacute; JM, et al; International Collaboration on Endocarditis. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the International Collaboration on Endocarditis. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6213-6222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24080644/pubmed\" target=\"_blank\" id=\"24080644\">24080644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. <i>Antimicrob Agents Chemother</i>. 2013;57(9):4190-4196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23774437/pubmed\" target=\"_blank\" id=\"23774437\">23774437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cha R, Grucz RG Jr, and Rybak MJ, &ldquo;Daptomycin Dose-Effect Relationship Against Resistant Gram-Positive Organisms,&rdquo; <i>Antimicrob Agents Chemother</i>, 2003, 47(5):1598-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/12709328/pubmed\" target=\"_blank\" id=\"12709328\">12709328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chakraborty A, Roy S, Loeffler J, et al, &ldquo;Comparison of the Pharmacokinetics, Safety and Tolerability of Daptomycin in Healthy Adult Volunteers Following Intravenous Administration by 30 Min Infusion or 2 Min Injection,&rdquo; <i>J Antimicrob Chemother</i>, 2009, 64(1):151-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19389714/pubmed\" target=\"_blank\" id=\"19389714\">19389714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24030545\"></a>Chaves RL, Chakraborty A, Benziger D, et al. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. <i>J Antimicrob Chemother.</i> 2014;69(1):200-210.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24030545/pubmed\" target=\"_blank\" id=\"24030545\">24030545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr, Smith PB. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. <i>Pediatr Infect Dis J</i>. 2012;31(9):935-937.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22627869/pubmed\" target=\"_blank\" id=\"22627869\">22627869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cubicin (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cubicin RF (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21327445\"></a>Das I, Saluja T, Steeds R. Use of daptomycin in complicated cases of infective endocarditis. <i>Eur J Clin Microbiol Infect Dis</i>. 2011;30(6):807-812.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21327445/pubmed\" target=\"_blank\" id=\"21327445\">21327445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23190763\"></a>Dohmen PM, Guleri A, Capone A, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. <i>J Antimicrob Chemother</i>. 2013;68(4):936-942.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23190763/pubmed\" target=\"_blank\" id=\"23190763\">23190763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. <i>Pharmacotherapy</i>. 2009;29(7):792-799.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19558253/pubmed\" target=\"_blank\" id=\"19558253\">19558253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haselden M, Leach M, Bohm N. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. <i>Ann Pharmacother.</i> 2013;47(10):1342-1347. doi: 10.1177/1060028013503110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24259698 /pubmed\" target=\"_blank\" id=\"24259698 \">24259698 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23299359\"></a>Kaya S, Yilmaz G, Kalkan A, Ertun&ccedil; B, K&ouml;ksal I. Treatment of gram-positive left-sided infective endocarditis with daptomycin. <i>J Infect Chemother</i>. 2013;19(4):698-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23299359/pubmed\" target=\"_blank\" id=\"23299359\">23299359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kielstein JT, Eugbers C, Bode-Boeger SM, et al, &ldquo;Dosing of Daptomycin in Intensive Care Unit Patients With Acute Kidney Injury Undergoing Extended Dialysis &ndash; A Pharmacokinetic Study,&rdquo; <i>Nephrol Dial Transplant</i>, 2010, 25(5):1537-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20031929/pubmed\" target=\"_blank\" id=\"20031929\">20031929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knoll BM, Spieler PJ, Kubiak DW, et al, &ldquo;Neutropenia Associated With Prolonged Daptomycin Use,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(9):1353-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23325425/pubmed\" target=\"_blank\" id=\"23325425\">23325425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15659542\"></a>Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. <i>J Antimicrob Chemother</i>. 2005;55(2):240-245.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/15659542/pubmed\" target=\"_blank\" id=\"15659542\">15659542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus Aureus</i> Infections in Adults and Children: Executive Summary,&rdquo; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marchand S, Lauda M, Le Moal G, et al. Pharmacokinetics of daptomycin in a patient with severe renal failure not receiving dialysis. <i>Antimicrob Agents Chemother.</i> 2013;57(6):2898-2899.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23545525 /pubmed\" target=\"_blank\" id=\"23545525 \">23545525 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller BA, Gray A, Leblanc TW, et al, &ldquo;Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(11):e63-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20420515/pubmed\" target=\"_blank\" id=\"20420515\">20420515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel N, Cardone K, Grabe DW, et al. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.<i> Antimicrob Agents Chemother.</i> 2011;55(4):1677-1683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21282429 /pubmed\" target=\"_blank\" id=\"21282429 \">21282429 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. <i>J Antimicrob Chemother</i>. 2015;70(3):643-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25406298/pubmed\" target=\"_blank\" id=\"25406298\">25406298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richter SS, Kealey DE, Murray CT, et al, &ldquo;The <i>in vitro</i> Activity of Daptomycin Against <i>Staphylococcus aureus</i> and <i>Enterococcus</i> Species,&rdquo; <i>J Antimicrob Chemother</i>, 2003, 52(1):123-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/12805265/pubmed\" target=\"_blank\" id=\"12805265\">12805265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salama NN, Segal JH, Churchwell MD, et al, &ldquo;Single-Dose Daptomycin Pharmacokinetics in Chronic Haemodialysis Patients,&rdquo; <i>Nephrol Dial Transplant</i>, 2010, 25(4):1279-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20007981/pubmed\" target=\"_blank\" id=\"20007981\">20007981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverman JA, Mortin LI, Vanpraagh AD, et al, &quot;Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact,&quot; <i>J Infect Dis</i>, 2005, 191(12):2149-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/15898002/pubmed\" target=\"_blank\" id=\"15898002\">15898002</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverman JA, Perlmutter NG, and Shapiro HM, &ldquo;Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in <i>Staphylococcus aureus</i>,&rdquo; <i>Antimicrob Agents Chemother</i>, 2003, 47(8):2538-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/12878516/pubmed\" target=\"_blank\" id=\"12878516\">12878516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tedeschi S, Tumietto F, Conti M, Giannella M, Viale P, S. Orsola Antimicrobial Stewardship Team. Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections.<i> Pediatr Infect Dis J</i>. 2016;35(2):180-182<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26484430/pubmed\" target=\"_blank\" id=\"26484430\">26484430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tedesco KL and Rybak MJ, &ldquo;Daptomycin,&rdquo; <i>Pharmacotherapy</i>, 2004, 24(1):41-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/14740787/pubmed\" target=\"_blank\" id=\"14740787\">14740787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vilay MA, Grio M, DePestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis [published correction appears in <i>Crit Care Med</i>. 2011;39(5):1247]. <i>Crit Care Med</i>, 2011, 39(1):19-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20890189/pubmed\" target=\"_blank\" id=\"20890189\">20890189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO), &quot;Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs&rdquo;. 2002. Available at: http://www.who.int/maternal_child_adolescent/documents/55732/en/.20890189</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9304 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156919\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6127324\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156936\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156921\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50085848\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156922\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F156923\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F1959284\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156900\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F156888\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F156904\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156903\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475182\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3265806\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156892\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156907\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156890\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299126\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156894\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156909\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6063936\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156898\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F156901\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156889\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F156906\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323093\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539841\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9304|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=daptomycin-patient-drug-information\" class=\"drug drug_patient\">Daptomycin: Patient drug information</a></li><li><a href=\"topic.htm?path=daptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Daptomycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}